Table 2 Laboratory confirmation of CMV infection and visual outcome of patients after specific antiviral therapy.
| Patient | Initial flare (ph/ms) | Diagnostic testing and results (CMV) | Systemic therapy | Topical treatment (at last follow up) | No of relapses (time after Rx) | Final IOP (mm Hg) | Final flare (ph/ms) | Final VA | Follow up (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | LAP+ | iv GCV | Rmx | 2 (after 6 and 12 months) | 18* | 14 | 20/30 | 24 |
| PCR+ ×2 | ValGCV | Drz | |||||||
| 2 | 28 | LAP+ | iv FCN | Rmx | 0 | 14 | 11 | 20/25 | 16 |
| PCR+ | ValGCV | Acl | |||||||
| 3 | 18 | LAP+ | ValGCV | Fmt | 1 (after 5 months) | 20 | 9 | 20/20 | 9 |
| PCR+ | ×2 | timolol | |||||||
| 4 | 16 | LAP+ | iv GCV | Rmx | 0 | 15 | 10 | 20/20 | 10 |
| PCR+ | ValGCV | timolol | |||||||
| 5 | ND | PCR+ ×2 | ValGCV | Prednisolone | 1 (1 month) | 20† | 42 | 20/25 | 24 |
| timolol |
Acl, apraclonidine; Drz, dorzolamide; FCN, foscarnet; Fmt, fluorometholone; GCV, ganciclovir; IOP, intraocular pressure; LAP, local antibody production; ND, not done; Rmx, rimexolone; Rx, treatment; VA, visual acuity; valGCV, valganciclovir.
*Required trabeculectomy †Required glaucoma drainage device.